DNLI Q1 2022 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+431.9% YoY

Gross Profit

$42M100.0% margin

Operating Income

-$66M-157.8% margin

Net Income

-$65M-154.8% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+236.8%

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$76M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$403M

Stockholders' Equity

$918M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$8M	+431.9%
Gross Profit	$42M	$8M	+431.9%
Operating Income	-$66M	-$71M	+6.6%
Net Income	-$65M	-$70M	+6.9%